Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Necitumumab plus gemcitabine and cisplatin in first-line stage IV squamous NSCLC
jRCT2080222039Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of necitumumab in Pulmonary squamous cell carcinoma (3 arms), sponsored by Eli Lilly and Company. Started Mar 2013; status: completed.
02
Drugs
necitumumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on jRCT2080222039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222039.